Health Canada Approves Innovotech Application for Agress(TM) Field Testing
June 08 2009 - 8:00AM
Marketwired
The Pest Management Regulatory Agency of Health Canada has granted
Innovotech (TSV VENTURE: IOT) a Research Authorization for
large-scale field trials for the 2009 season to test its novel seed
treatment, Agress(TM). This Research Authorization provides growers
with an opportunity to assess the real-world ability of Agress(TM)
to fight bacterial disease and its ease of use. In conjunction with
cooperating growers, dry beans treated with Agress(TM) have been
planted on farms in Alberta.
"These large-scale field trials give us an opportunity to test
Agress(TM) on a commercial scale that would be used by a grower,"
says Damian Sowa, Product Manager, Innovotech. "We will also use
the trials to validate our small plot results that showed
Agress(TM) to be a superior and long sought replacement for
Streptomycin in bacterial infestations of beans."
Research is currently underway to expand the applications of
AgressTM to include the major crops in North America and additional
disease classes.
About Innovotech Inc:
Innovotech is a product development company focusing on the
development of solutions to medical, agricultural and industrial
problems caused by microbial biofilms. Biofilms are protected
communities of microorganisms which are very common and very
difficult to treat due to their inherent resistance. The company
currently has two products in advanced stages of development:
bioFILM PA is a diagnostic kit which assists physicians in the
selection of the most effective antibiotic treatment of patients
with chronic lung infections. AgressTM is a novel seed treatment
product which protects seeds during the critical germination and
emergence stage from bacterial and fungal infection. Both products
were developed against the corresponding organisms present as
biofilms as opposed to the free-floating, planktonic form.
This document contains forward-looking statements that are
predictive in nature and subject to risks and uncertainties that
cannot be predicted or quantified; consequently, actual results may
differ materially from past results and those expressed or implied
by any forward-looking statements. Factors that could cause or
contribute to such risks or uncertainties include, but are not
limited to: the regulatory environment including the difficulty of
predicting regulatory outcomes; changes in the value of the
Canadian dollar; the Company's reliance on a small number of
customers including government organizations; fluctuations in
operating results; government policies or actions; progress and
cost of clinical trials; reliance on key strategic relationships;
uncertainty related to intellectual property protection and
potential costs associated with its defense; the Company's exposure
to lawsuits and other matters beyond the control of management.
Should known or unknown risks or uncertainties materialize, or
should management's assumptions prove inaccurate, actual results
could vary materially from those anticipated. The Company
undertakes no obligation to publicly make or update any
forward-looking statements, except as required by applicable
law.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Contacts: Innovotech Inc. Ken Boutilier President & CEO
(780) 448-0585 ext 221 (780) 424-0941 (FAX) Email:
ken.boutilier@innovotech.ca
Innovotech (TSXV:IOT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Innovotech (TSXV:IOT)
Historical Stock Chart
From Jul 2023 to Jul 2024